Diagnosis of congenital Trypanosoma cruzi infection: A serologic test using Shed Acute Phase Antigen (SAPA) in mother–child binomial samples

Volta, Bibiana Julieta; Russomando, Graciela; Bustos, Patricia Laura; Scollo, Karenina; Rissio, Ana María De; Sánchez, Zunilda; Cardoni, Rita L.; Búa, Jacqueline

doi:10.1016/j.actatropica.2015.03.026

Cited by 14 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other tests detecting antibodies in blood, such as trypomastigote excreted-secreted antigens blots IgM or shed acute-phase antigens (SAPA) ELISA IgG (detecting SAPA within the first 3 months of infection [22, 40]), are not commercially available and need to be validated at a larger scale.…”

Section: Recommendations For Laboratory Diagnosismentioning

confidence: 99%

Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women

et al. 2019

View full text Add to dashboard Cite

Section: Recommendations For Laboratory Diagnosismentioning

confidence: 99%

Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women

et al. 2019

View full text Add to dashboard Cite

“…An ELISA test available in Paraguay detects anti-SAPA IgG antibodies in children born to infected mothers at 3 months of age (Russomando et al., 2010). The anti-SAPA IgG levels in binomial blood samples from seropositive mothers and their babies also allowed for diagnosis in 90.5% of the T. cruzi- infected children at around 1 month of age (Volta et al., 2015) by subtracting the anti-SAPA OD value of the mother from the one in the child (Mallimaci et al., 2010). We observed a positive correlation between parasitemia levels in mothers and infants, evaluated by qPCR, and the anti-SAPA IgG antibody titers detected by ELISA, which more likely accounts for the secretion of SAPA antigen by the trypomastigotes in the bloodstream (Volta et al., 2015).…”

Section: Search Of Biomarkers For the Early Serological Diagnosis Of mentioning

confidence: 99%

Trypanosoma cruzi Infection at the Maternal-Fetal Interface: Implications of Parasite Load in the Congenital Transmission and Challenges in the Diagnosis of Infected Newborns

et al. 2019

Self Cite

View full text Add to dashboard Cite

Trypanosoma cruzi is the protozoan unicellular parasite that causes Chagas disease. It can be transmitted from infected mothers to their babies via the connatal route, thus being able to perpetuate even in the absence of Triatomine insect vectors. Chagas disease was originally endemic in Central and South America, but migration of infected women of childbearing age has spread the T. cruzi congenital infection to non-endemic areas like North America, Europe, Japan, and Australia. Currently, 7 million people are affected by this infection worldwide. This review focuses on the relevance of the T. cruzi parasite levels in different aspects of the congenital T. cruzi infection such as the mother-to-child transmission rate, the maternal and fetal immune response, and its impact on the diagnosis of infected newborns. Improvements in detection of this parasite, with tools that can be easily adapted to be used in remote rural areas, will make the early diagnosis of infected children possible, allowing a prompt trypanocidal treatment and avoiding the current loss of opportunities for the diagnosis of 100% of T. cruzi congenitally infected infants.

show abstract

“…Up to this day, SAPA remains the only available serological marker of early infection and has been widely used to diagnose recently-acquired vector-borne infections and congenitally transmitted cases (Mallimaci et al, 2010; Russomando et al, 2010; Volta et al, 2015). …”

Section: Diagnostic Applications For Chagas D Isease: Pending Issuesmentioning

confidence: 99%

Chagas Disease Diagnostic Applications

Balouz

Agüero

Buscaglia

2017

Advances in Parasitology

View full text Add to dashboard Cite

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a life-long and debilitating illness of major significance throughout Latin America, and an emergent threat to global public health. Being a neglected disease, the vast majority of Chagasic patients have limited access to proper diagnosis and treatment, and there is only a marginal investment into R&D for drug and vaccine development. In this context, identification of novel biomarkers able to transcend the current limits of diagnostic methods surfaces as a main priority in Chagas disease applied research. The expectation is that these novel biomarkers will provide reliable, reproducible and accurate results irrespective of the genetic background, infecting parasite strain, stage of disease, and clinical-associated features of Chagasic populations. In addition, they should be able to address other still unmet diagnostic needs, including early detection of congenital T. cruzi transmission, rapid assessment of treatment efficiency or failure, indication/prediction of disease progression and direct parasite typification in clinical samples. The lack of access of poor and neglected populations to essential diagnostics also stress the necessity of developing new methods operational in Point-of-Care (PoC) settings. In summary, emergent diagnostic tests integrating these novel and tailored tools should provide a significant impact on the effectiveness of current intervention schemes and on the clinical management of Chagasic patients. In this chapter, we discuss the present knowledge and possible future steps in Chagas disease diagnostic applications, as well as the opportunity provided by recent advances in high-throughput methods for biomarker discovery.

show abstract

Diagnosis of congenital Trypanosoma cruzi infection: A serologic test using Shed Acute Phase Antigen (SAPA) in mother–child binomial samples

Cited by 14 publications

References 20 publications

Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women

Congenital Chagas disease: Updated recommendations for prevention, diagnosis, treatment, and follow-up of newborns and siblings, girls, women of childbearing age, and pregnant women

Trypanosoma cruzi Infection at the Maternal-Fetal Interface: Implications of Parasite Load in the Congenital Transmission and Challenges in the Diagnosis of Infected Newborns

Chagas Disease Diagnostic Applications

Contact Info

Product

Resources

About